DIETHYLCARBAMAZINE PAMOATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H16O6.C10H21N3O
Molecular Weight	587.6628
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C(=O)N1CCN(C)CC1.OC(=O)C2=CC3=C(C=CC=C3)C(CC4=C5C=CC=CC5=CC(C(O)=O)=C4O)=C2O

InChI

InChIKey=BDLFTHFBZRBSSL-UHFFFAOYSA-N

InChI=1S/C23H16O6.C10H21N3O/c24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29;1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h1-10,24-25H,11H2,(H,26,27)(H,28,29);4-9H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C10H21N3O
Molecular Weight	199.2932
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C23H16O6
Molecular Weight	388.3695
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.html
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

Diethylcarbamazine is used in humans, dogs and cats for the treatment of parasitic infections, including pulmonary eosinophilia, loiasis, and lymphatic filariasis. The exact mechanism of its action is unknown, however some studies showed the involvment of inducible nitric-oxide synthase and the cyclooxygenase pathway. Although there is no information on whether the drug is marketed in the USA and Europe, it is currently used in India.

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Tropical pulmonary eosinophilia 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8429	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Loiasis 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8429	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.
Lymphatic filariasis 3 Sources: http://india-pharma.gsk.com/media/701051/banocide-and-banocide-forte.pdf	Curative	Approved 8429	BANOCIDE Approved Use Used for the treatment of individual patients with certain filarial diseases including tropical pulmonary eosinophilia, loiasis, and lymphatic filariasis caused by infection with Wuchereria bancrofti, Brugia malayi, or Brugia timori.

C_max

Value	Dose	Co-administered	Analyte	Population
500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
637 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5840 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
7220 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
14.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
11.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11865970/	150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered:		DIETHYLCARBAMAZINE serum	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED

Doses

Dose	Population	Adverse events
6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	Other AEs: Fever, Pruritus... Other AEs: Fever (63.6%) Pruritus (9.1%) Giddiness (9.1%) Joint ache (9.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	Other AEs: Fever, Nausea... Other AEs: Fever Nausea (27.3%) Vomiting (18.2%) Abdominal discomfort (9.1%) Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Papular urticarial eruption (30%) Proteinuria (10%) Visual field constriction (20%) Optic nerve pallor (10%) Corneal opacity (90%) Anterior uveitis (10%) Chorioretinitis (10%) Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	Other AEs: Lymphadenopathy, Papular urticarial eruption... Other AEs: Lymphadenopathy (100%) Papular urticarial eruption (70%) Proteinuria (30%) Visual field constriction (10%) Optic nerve pallor (20%) Corneal opacity (80%) Anterior uveitis (30%) Chorioretinitis (30%) Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	Other AEs: Fatigue, Nausea... Other AEs: Fatigue (grade 2, 5%) Nausea (grade 2, 2%) Vomiting (grade 2, 2%) Joint pain (grade 2, 2%) Eye swelling (grade 2, 2%) Rash (grade 2, 2%) Dyspnea (grade 2, 2%) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	Other AEs: Fever, Headache... Other AEs: Fever (69%) Headache (65%) Vertigo (57%) Malaise (49%) Chills (45%) Joint pain (40%) Abdominal pain (37%) Chest pain (33%) Nausea (28%) Neck pain (24%) Vomiting (16%) Muscular pain (14%) Lymph node tenderness (38%) Epididymal tenderness (34%) Nodule (15%) Tinnitus (8%) Convulsion (2%) Eruption (<1%) Shock (<1%) Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737 inhibitor 1587	inhibitor 1767	inhibitor 1852

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2C19 1478 OATP1B1 788 OATP1B3 706	CYP1A2 1054 CYP2B6 664 P-gp 1537	CYP1A 56

Drug as perpetrator

Target	Modality	Activity
CYP2C19 1553	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	no [Activation >10 uM]
CYP1A 121	inducer 1573 Sources: https://pubmed.ncbi.nlm.nih.gov/12451431/	no
CYP1A2 1692	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
CYP2C9 1819	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
CYP2D6 1891	inhibitor 3277 Sources: https://link.springer.com/article/10.1007/BF00202169	no
CYP3A4 1925	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	no
OATP1B1 803	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	yes [Inhibition 10 uM]
OATP1B3 715	inhibitor 3277 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzNyJ9fQ%3D%3D	yes [Inhibition 10 uM]
CYP2C19 1553	activator 214 Sources: https://dmd.aspetjournals.org/content/29/1/30.short	yes

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP1A2 1054	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12920490/	likely
CYP2B6 664	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/12920490/	likely
CYP3A4 1737	substrate 3367 Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950	no	no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950
P-gp 1537	substrate 3367 Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950	no	no (co-administration study) Comment: Coadministration of refampicin/ketoconazole did not affect the exposure of diethylcarbamazine. Sources: http://smj.medicine.psu.ac.th/index.php/smj/article/view/950

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY578639	https://www.001chemical.com/chem/90-89-1
3B Scientific (Wuhan) Corp	3B3-061821	http://www.3bsc.com/index/pro_info.php?id=100910
AA Blocks	AA00IFVB	http://www.aablocks.com/goods/Goods/detail?id=AA00IFVB
AEchem Scientific Corp., USA	AE028779	http://www.aechemsc.com/info_products/AE028779.php
Aaron Chemicals	AR00IGN3	http://www.aaronchem.com/90-89-1
Achemo Scientific Limited	AC-89305	http://www.achemo.com/search/?Keyword= 90-89-1
Alichem	490014501	http://www.alichem.com/en/products/90-89-1.html
Angene	AGN-PC-0JK6FF	http://www.angenechemical.com/productshow/AGN-PC-0JK6FF.html
Ark Pharm	AK158485	http://www.arkpharminc.com/products/90-89-1.html
Ark Pharma Scientific Limited	H-012789	http://www.arkpharmtech.com/product/17844.html
Aurora Fine Chemicals LLC	A13.142.491	http://online.aurorafinechemicals.com/info?ID=A13.142.491
Aurum Pharmatech LLC	NE55264	http://www.Aurumpharmatech.com/Product/ProductDetails/NE55264
BLD Pharm	BD23082	http://www.bldpharm.com/products/90-89-1.html
ChemMol	99173714	http://www.chemmol.com/chemmol/99173714.html
Chemspace	CSSB00000693863	https://chem-space.com/CSSB00000693863
Clearsynth	CS-MM-79413	https://www.clearsynth.com/en/CSMM79413.html
Debye Scientific	DB-080764	http://www.debyesci.com/cas_90-89-1.html
Finetech	FT-0624832	http://www.finetechnology-ind.com/prod/detail/pub/90-89-1.html
Frinton	FR-1031	https://www.frinton.com/search/?filtername=NN-Diethyl-4-methyl-1-piperazinecarboxamide
Lab Network	LN01325414	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01325414
Matrix Scientific	172278	https://www.matrixscientific.com/172278.html
Molcore	MC578639	https://www.molcore.com/product/90-89-1
Parchem	28724	http://www.parchem.com/chemical-supplier-distributor/Diethyl-Carbamazine-Citrate-018724.aspx
R&D Chemicals	FR-1031	http://www.rdchemicals.com/chemicals.php?mode=details&mol_id=2751
Sigma-Aldrich	PH003578_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/ph003578
Smolecule	S526027	http://www.smolecule.com/products/s526027
THE BioTek	bt-264510	https://www.thebiotek.com/product/inhibitors/bt-264510
Yuhao Chemical	XJ0184	http://www.chemyuhao.com/90-89-1.html
abcr GmbH	AB357734	http://www.abcr.com/shop/en/AB357734
eNovation Chemicals	Y0988700	https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0988700
iChemical	EBD3427	http://www.ichemical.com/chemicals/cas-90-89-1
mcule	MCULE-7296820622	https://mcule.com/MCULE-7296820622/

PubMed

Title	Date	PubMed
Possible atypical cross-sensitivity between phenytoin and carbamazepine in the anticonvulsant hypersensitivity syndrome.	2001 Apr	11310525
Relationship between microfilaria count and sensitivity of the direct smear for diagnosis of canine dirofilariosis.	2001 Jan 1	11113550
Tropical pulmonary eosinophilia and filariasis in Pakistan.	2001 Mar	11485099
Migration and dispersal of lymphatic filariasis in Papua New Guinea.	2001 May-Jun	11490996
Severe hepatic involvement in visceral larva migrans.	2001 Oct	11711784
Histamine stimulates alveolar macrophages to release neutrophil and monocyte chemotactic activity.	2001 Oct	11574816
Anthelmintics: a review.	2001 Oct-Dec	11963321
Lymphatic filariasis in children: adenopathy and its evolution in two young girls.	2001 Sep	11561705
Progress towards, and challenges for, the elimination of filariasis from Pacific-island communities.	2002 Dec	12625919
Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods.	2002 Dec	12553573
Bancroftian filariasis: clinical parasitologic and serologic evaluation after 4 years applying two antifilarial regimens.	2002 Dec	12512817
Resurgence in filarial transmission after withdrawal of mass drug administration and the relationship between antigenaemia and microfilaraemia--a longitudinal study.	2002 Jan	11851956
Targeting of children in filariasis mass drug administration.	2002 Nov 2	12424026
Microfilaria in a thyroid nodule which resolved on treatment.	2002 Oct	12405321
The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.	2002 Sep	12396323
Targeting apoptotic signalling pathway and pro-inflammatory cytokine expression as therapeutic intervention in TPE induced lung damage.	2003	12788054
A comparison of the efficacy of single doses of albendazole, ivermectin, and diethylcarbamazine alone or in combinations against Ascaris and Trichuris spp.	2003	12640474
Strategic options for global lymphatic filariasis elimination.	2003 May	12763424
Ensuring supplies of quality diethylcarbamazine citrate (DEC).	2003 May	12751269
Lymphatic filariasis.	2003 May 16	12808788

Sample Use Guides

In Vivo Use Guide

Lymphatic filariasis: 6 mg/kg daily for 12 days administered orally, preferably in divided doses after meals (W. bancrofti infection); 3-6 mg/kg daily for 6-12 days administered orally, preferably in divided doses after meals (B. malayi and B. timori infections). Tropical pulmonary eosinophilia: a dose of 8 mg/kg daily for 14 days repeated, as necessary, if symptoms return.

Route of Administration: Oral

In Vitro Use Guide

Larvae of nocturnally subperiodic Brugia malayi was inhibited under incubation with diethylcarbamazine at concentration of 10(-5) M.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:24:38 GMT 2023` Edited by `admin` on `Fri Dec 15 15:24:38 GMT 2023`
Record UNII	X8816G8TOP
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

DIETHYLCARBAMAZINE PAMOATE

Common Name

English

DIETHYLCARBAMAZINE EMBONATE

Common Name

English

N,N-DIETHYL-4-METHYL-1-PIPERAZINECARBOXAMIDE PAMOATE

Common Name

English

2-NAPHTHALENECARBOXYLIC ACID, 4,4'-METHYLENEBIS(3-HYDROXY-, COMPD. WITH N,N-DIETHYL-4-METHYL-1-PIPERAZINECARBOXAMIDE (1:1)

Common Name

English

Code System Code Type Description

FDA UNII

X8816G8TOP

Created by admin on Fri Dec 15 15:24:38 GMT 2023 , Edited by admin on Fri Dec 15 15:24:38 GMT 2023

PRIMARY

CAS

56973-50-3

Created by admin on Fri Dec 15 15:24:38 GMT 2023 , Edited by admin on Fri Dec 15 15:24:38 GMT 2023

PRIMARY

EPA CompTox

DTXSID40205577

Created by admin on Fri Dec 15 15:24:38 GMT 2023 , Edited by admin on Fri Dec 15 15:24:38 GMT 2023

PRIMARY

PUBCHEM

13475824

Created by admin on Fri Dec 15 15:24:38 GMT 2023 , Edited by admin on Fri Dec 15 15:24:38 GMT 2023

PRIMARY

Related Record Type Details


					V867Q8X3ZD

DIETHYLCARBAMAZINE

PARENT -> SALT/SOLVATE


					7RRQ8QZ38N

PAMOIC ACID

PARENT -> SALT/SOLVATE

Related Record Type Details


					V867Q8X3ZD

DIETHYLCARBAMAZINE

ACTIVE MOIETY

AE	Significance	Dose	Population
Fever	63.6%	6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Giddiness	9.1%	6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Joint ache	9.1%	6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Pruritus	9.1%	6 mg/kg 1 times / day multiple, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: multiple Dose: 6 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 12 to 69 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 12 to 69 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Fever		2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Vomiting	18.2%	2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Nausea	27.3%	2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Abdominal discomfort	9.1%	2 mg/kg 3 times / day multiple, oral Studied dose Dose: 2 mg/kg, 3 times / day Route: oral Route: multiple Dose: 2 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/	unhealthy, 13 to 46 years n = 11 Health Status: unhealthy Condition: filariasis Age Group: 13 to 46 years Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/7001687/
Anterior uveitis	10%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Chorioretinitis	10%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Optic nerve pallor	10%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Proteinuria	10%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Lymphadenopathy	100%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Visual field constriction	20%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Papular urticarial eruption	30%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Corneal opacity	90%	50 mg multiple, oral Studied dose Dose: 50 mg Route: oral Route: multiple Dose: 50 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 37 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 37 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Visual field constriction	10%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Lymphadenopathy	100%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Optic nerve pallor	20%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Anterior uveitis	30%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Chorioretinitis	30%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Proteinuria	30%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Papular urticarial eruption	70%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Corneal opacity	80%	300 mg multiple, topical Studied dose Dose: 300 mg Route: topical Route: multiple Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/	unhealthy, 40 years n = 10 Health Status: unhealthy Condition: onchocerciasis Age Group: 40 years Sex: M Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/6103299/
Dyspnea	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Eye swelling	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Joint pain	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Nausea	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Rash	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Vomiting	grade 2, 2%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Fatigue	grade 2, 5%	6 mg/kg 1 times / day single, oral Studied dose Dose: 6 mg/kg, 1 times / day Route: oral Route: single Dose: 6 mg/kg, 1 times / day Co-administed with:: ivermectin(200 ug/kg; single) albendazole(400 mg; single) Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/	unhealthy, median age 35 years n = 43 Health Status: unhealthy Condition: Filariasis Age Group: median age 35 years Sex: M+F Population Size: 43 Sources: https://pubmed.ncbi.nlm.nih.gov/31641754/
Muscular pain	14%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Nodule	15%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Vomiting	16%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Convulsion	2%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Neck pain	24%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Nausea	28%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Chest pain	33%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Epididymal tenderness	34%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Abdominal pain	37%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Lymph node tenderness	38%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Joint pain	40%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Chills	45%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Malaise	49%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Vertigo	57%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Headache	65%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Fever	69%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Tinnitus	8%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Eruption	<1%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/
Shock	<1%	8 mg/kg 3 times / day multiple, oral (mean) Studied dose Dose: 8 mg/kg, 3 times / day Route: oral Route: multiple Dose: 8 mg/kg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/	unhealthy n = 972 Health Status: unhealthy Condition: filariasis Sex: M+F Population Size: 972 Sources: https://pubmed.ncbi.nlm.nih.gov/1463361/

Details

SMILES

InChI

DescriptionSources: http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.htmlCurator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

Approval Year

Conditions

Approved Use

Approved Use

Approved Use

Cmax

AUC

T1/2

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Sourcing

PubMed

Sample Use Guides

Description
Sources: http://apps.who.int/medicinedocs/en/d/Jh2922e/3.5.1.html
Curator's Comment: description was created based on several sources, including http://filobase.bicpu.edu.in/banocide.pdf

C_max

T_1/2

Drug as perpetrator